The patented, GMO-free formulation has found much success internationally, as it is in over 25+ countries.  Baby Colic™ is part of the Floradapt Probiotic Portfolio, which are products based on a mechanistic approach to identify optimal strains for specific health applications. Our strain library collection has over 1,000+ different wild-type strains, strategically sourced from populations around the world with conserved microbiomes. Floradapt includes strains for Cardio, Intensive GI, Digestive, Gum Health, Mature Immune Defense, Urinary Tract Health, and Vaginal Health. Floradapt’s efficacy is rooted in its clinical strains, and accomplished through a unique mechanism of action (MoA) not seen in other probiotic products.

Dr Fumiki Aoki, Business Development Director, Probiotics Division, adds ”Baby Colic performs excellently well in the clinical studies, which has demonstrated reduced excess crying and helps reduce the duration of the crying episode, due to infant colic.  Floradapt™ Baby Colic is recommended for breast-fed and bottle-fed babies. Our dual clinical strains formulation are comprised of patented strains of Pediococcus pentosaceus and Bifidobacterium longum, in an easily utilized liquid-dropper format. Furthermore, we have confirmed our results in two double-blind, randomized, placebo controlled designed studies. The end result is parents can look forward to reduced crying-time by more than 60% after only 2 weeks administration.”

Kaneka has once again created a probiotic product that speaks directly to the natural dietary supplement consumer. Kaneka is committed to promoting business development to provide solutions that support healthy and energetic lives.